Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before ...

A hidden “jack-in-the-box” mechanism inside T cells may hold the key to unlocking more powerful cancer immunotherapies.

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by ...